Role of t cell subsets in lacrimal gland disease in MRL/Mp-Iprllpr mice

Douglas Jabs, R. A. Prendergast

Research output: Contribution to journalArticle

Abstract

Purpose. MRL/Mp-lpr/lpr mice (MRL/lpr) spontaneously develop an autoimmune disease, including lacrimal gland lesions, which are a model for Sjögren's syndrome. Target organ lesions in MRL/lpr mice are composed largely of CD4+ T cells, and Ireatment with monoclonal antibodies (mAb) against CD4 improves in the systemic autoimmune disease but not the lacrimal gland inflammation. In anti-CD4 mAb-treated MRL/lpr mice the lacrimal gland lesions are composed largely of CD8+ T cells. The effects of depletion of. 1 ) only CD8+ T cells and 2) both CD4+ and CD8+ T cells on the lacrimal gland disease were investigated. Methods. MRL/lpr mice were treated with weekly injections of either: 1) 2 mg anti-CD4 mAb and 5 mg anti-CD8; or 2) 5 mg anti-CD8 alone. Control mice underwent similar treatment with either saline or rig injections. Results. Combined anti-CD4 and anti-CD8 therapy was effective in reducing the lacrimal gland disease in terms of frequency {25% £grade 3 vs 93% in controls, P=0.002) and extent (median 0% of lacrimal gland involved by inflammation vs 12 9% in controls, P=0.0005). Treatment with anti-CD8 mAb therapy alone was ineffective. The systemic autoimmune disease was also improved by combined antiCD4 and anti-CD8 mAb therapy but not by anti-CD8 mAb therapy aJone. Conclusions. Suppression of both CD4+ and CD8+ T cells is required to suppress lacrimal gland inflammation in MRL/lpr mice. CD4-CD8- TCR cc/β+ "double negative" T cells, which are massively increased in number in the lymph nodes of MRL/lpr mice, do not appear to contribute to the lacrimal gland disease.

Original languageEnglish (US)
JournalInvestigative Ophthalmology and Visual Science
Volume38
Issue number4
StatePublished - Dec 1 1997

Fingerprint

Lacrimal Apparatus
Monoclonal Antibodies
T-Lymphocytes
Autoimmune Diseases
Inflammation
Therapeutics
Injections
Lymph Nodes

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Role of t cell subsets in lacrimal gland disease in MRL/Mp-Iprllpr mice. / Jabs, Douglas; Prendergast, R. A.

In: Investigative Ophthalmology and Visual Science, Vol. 38, No. 4, 01.12.1997.

Research output: Contribution to journalArticle

@article{e6c6ccbe393141799dd6191bb2e0c7d8,
title = "Role of t cell subsets in lacrimal gland disease in MRL/Mp-Iprllpr mice",
abstract = "Purpose. MRL/Mp-lpr/lpr mice (MRL/lpr) spontaneously develop an autoimmune disease, including lacrimal gland lesions, which are a model for Sj{\"o}gren's syndrome. Target organ lesions in MRL/lpr mice are composed largely of CD4+ T cells, and Ireatment with monoclonal antibodies (mAb) against CD4 improves in the systemic autoimmune disease but not the lacrimal gland inflammation. In anti-CD4 mAb-treated MRL/lpr mice the lacrimal gland lesions are composed largely of CD8+ T cells. The effects of depletion of. 1 ) only CD8+ T cells and 2) both CD4+ and CD8+ T cells on the lacrimal gland disease were investigated. Methods. MRL/lpr mice were treated with weekly injections of either: 1) 2 mg anti-CD4 mAb and 5 mg anti-CD8; or 2) 5 mg anti-CD8 alone. Control mice underwent similar treatment with either saline or rig injections. Results. Combined anti-CD4 and anti-CD8 therapy was effective in reducing the lacrimal gland disease in terms of frequency {25{\%} £grade 3 vs 93{\%} in controls, P=0.002) and extent (median 0{\%} of lacrimal gland involved by inflammation vs 12 9{\%} in controls, P=0.0005). Treatment with anti-CD8 mAb therapy alone was ineffective. The systemic autoimmune disease was also improved by combined antiCD4 and anti-CD8 mAb therapy but not by anti-CD8 mAb therapy aJone. Conclusions. Suppression of both CD4+ and CD8+ T cells is required to suppress lacrimal gland inflammation in MRL/lpr mice. CD4-CD8- TCR cc/β+ {"}double negative{"} T cells, which are massively increased in number in the lymph nodes of MRL/lpr mice, do not appear to contribute to the lacrimal gland disease.",
author = "Douglas Jabs and Prendergast, {R. A.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "38",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "4",

}

TY - JOUR

T1 - Role of t cell subsets in lacrimal gland disease in MRL/Mp-Iprllpr mice

AU - Jabs, Douglas

AU - Prendergast, R. A.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Purpose. MRL/Mp-lpr/lpr mice (MRL/lpr) spontaneously develop an autoimmune disease, including lacrimal gland lesions, which are a model for Sjögren's syndrome. Target organ lesions in MRL/lpr mice are composed largely of CD4+ T cells, and Ireatment with monoclonal antibodies (mAb) against CD4 improves in the systemic autoimmune disease but not the lacrimal gland inflammation. In anti-CD4 mAb-treated MRL/lpr mice the lacrimal gland lesions are composed largely of CD8+ T cells. The effects of depletion of. 1 ) only CD8+ T cells and 2) both CD4+ and CD8+ T cells on the lacrimal gland disease were investigated. Methods. MRL/lpr mice were treated with weekly injections of either: 1) 2 mg anti-CD4 mAb and 5 mg anti-CD8; or 2) 5 mg anti-CD8 alone. Control mice underwent similar treatment with either saline or rig injections. Results. Combined anti-CD4 and anti-CD8 therapy was effective in reducing the lacrimal gland disease in terms of frequency {25% £grade 3 vs 93% in controls, P=0.002) and extent (median 0% of lacrimal gland involved by inflammation vs 12 9% in controls, P=0.0005). Treatment with anti-CD8 mAb therapy alone was ineffective. The systemic autoimmune disease was also improved by combined antiCD4 and anti-CD8 mAb therapy but not by anti-CD8 mAb therapy aJone. Conclusions. Suppression of both CD4+ and CD8+ T cells is required to suppress lacrimal gland inflammation in MRL/lpr mice. CD4-CD8- TCR cc/β+ "double negative" T cells, which are massively increased in number in the lymph nodes of MRL/lpr mice, do not appear to contribute to the lacrimal gland disease.

AB - Purpose. MRL/Mp-lpr/lpr mice (MRL/lpr) spontaneously develop an autoimmune disease, including lacrimal gland lesions, which are a model for Sjögren's syndrome. Target organ lesions in MRL/lpr mice are composed largely of CD4+ T cells, and Ireatment with monoclonal antibodies (mAb) against CD4 improves in the systemic autoimmune disease but not the lacrimal gland inflammation. In anti-CD4 mAb-treated MRL/lpr mice the lacrimal gland lesions are composed largely of CD8+ T cells. The effects of depletion of. 1 ) only CD8+ T cells and 2) both CD4+ and CD8+ T cells on the lacrimal gland disease were investigated. Methods. MRL/lpr mice were treated with weekly injections of either: 1) 2 mg anti-CD4 mAb and 5 mg anti-CD8; or 2) 5 mg anti-CD8 alone. Control mice underwent similar treatment with either saline or rig injections. Results. Combined anti-CD4 and anti-CD8 therapy was effective in reducing the lacrimal gland disease in terms of frequency {25% £grade 3 vs 93% in controls, P=0.002) and extent (median 0% of lacrimal gland involved by inflammation vs 12 9% in controls, P=0.0005). Treatment with anti-CD8 mAb therapy alone was ineffective. The systemic autoimmune disease was also improved by combined antiCD4 and anti-CD8 mAb therapy but not by anti-CD8 mAb therapy aJone. Conclusions. Suppression of both CD4+ and CD8+ T cells is required to suppress lacrimal gland inflammation in MRL/lpr mice. CD4-CD8- TCR cc/β+ "double negative" T cells, which are massively increased in number in the lymph nodes of MRL/lpr mice, do not appear to contribute to the lacrimal gland disease.

UR - http://www.scopus.com/inward/record.url?scp=33749157566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749157566&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749157566

VL - 38

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 4

ER -